ArticleJournal of clinical immunology2024

Ruxolitinib Improves Immune-Dysregulation Features but not Epigenetic Abnormality in a Patient with STAT1 GOF.

June-Young Koh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.